scispace - formally typeset
C

Constantinos Koumenis

Researcher at University of Pennsylvania

Publications -  156
Citations -  15751

Constantinos Koumenis is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Unfolded protein response & Tumor microenvironment. The author has an hindex of 52, co-authored 129 publications receiving 13837 citations. Previous affiliations of Constantinos Koumenis include Wake Forest University & Wake Forest Baptist Medical Center.

Papers
More filters
Journal ArticleDOI

Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis.

TL;DR: The hypothesis that oncogenic signals in the absence of gene expression are sufficient to induce cell death is tested, which would indicate that constitutive expression of antiapoptotic genes is necessary for maintenance of the transformed state, and inhibition of RNAP II may be exploited therapeutically for the design of successful antitumor agents.
Journal ArticleDOI

Thioredoxin Reductase-1 Mediates Curcumin-Induced Radiosensitization of Squamous Carcinoma Cells

TL;DR: It is reported that an inhibitory activity of curcumin on the antioxidant enzyme thioredoxin reductase-1 (TxnRd1) is required forCurcumin-mediated radiosensitization of squamous carcinoma cells and suggested that TxnRD1 levels in tumors could have clinical value as a predictor of response to curcuming and radiotherapy.
Journal ArticleDOI

Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy.

TL;DR: The main mechanisms by which tumor cells overcome ER stress to promote their survival, tumor progression and metastasis are described and the current state of efforts to develop therapeutic approaches of targeting the UPR are discussed.
Journal ArticleDOI

c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma

TL;DR: Findings illustrate a mechanism that controls aberrant tumor vascularization and suggest that targeting Endo-MT may offer selective and efficient strategies for antivascular and vessel normalization therapies in GBM, and possibly other malignant tumors.